版本:
中国

BRIEF-Jazz Pharmaceuticals presents data for study of JZP-110 in patients

June 6 Jazz Pharmaceuticals Plc

* Jazz Pharmaceuticals presents data for the phase 3 tones 2 study of JZP-110 in patients with excessive sleepiness associated with narcolepsy

* ‍study demonstrated statistically significant effects of both 150 mg and 300 mg doses of JZP-110 on co-primary endpoints​

* JZP-110 U.S. NDA submission planned for later this year Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐